Zacks Investment Research downgraded shares of Natera (NASDAQ:NTRA) from a hold rating to a sell rating in a report published on Thursday morning.
According to Zacks, “Natera, Inc. offers genetic testing and diagnostics with proprietary bioinformatics and molecular technology. Natera, Inc. is headquartered in San Carlos, California. “
Several other research analysts have also recently weighed in on NTRA. BidaskClub upgraded Natera from a strong sell rating to a sell rating in a research note on Friday, December 7th. ValuEngine cut Natera from a strong-buy rating to a buy rating in a research report on Wednesday, January 9th. Finally, Canaccord Genuity reiterated a buy rating and set a $25.00 price objective on shares of Natera in a research report on Monday, March 11th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Natera currently has a consensus rating of Buy and an average price target of $27.75.
Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Tuesday, March 12th. The medical research company reported ($0.51) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.51). Natera had a negative return on equity of 790.13% and a negative net margin of 49.72%. The firm had revenue of $67.00 million during the quarter, compared to analysts’ expectations of $62.87 million. As a group, analysts anticipate that Natera will post -2.24 earnings per share for the current year.
In other Natera news, CTO Jonathan Sheena sold 3,043 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $48,688.00. Following the completion of the sale, the chief technology officer now owns 240,201 shares in the company, valued at $3,843,216. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Matthew Rabinowitz sold 5,672 shares of the company’s stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $16.00, for a total value of $90,752.00. Following the completion of the sale, the insider now owns 1,288,853 shares of the company’s stock, valued at approximately $20,621,648. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,194 shares of company stock valued at $742,949. Company insiders own 13.18% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Great West Life Assurance Co. Can boosted its stake in shares of Natera by 136.8% in the fourth quarter. Great West Life Assurance Co. Can now owns 5,920 shares of the medical research company’s stock worth $80,000 after acquiring an additional 3,420 shares during the period. Legal & General Group Plc boosted its stake in shares of Natera by 14.5% in the fourth quarter. Legal & General Group Plc now owns 5,826 shares of the medical research company’s stock worth $81,000 after acquiring an additional 736 shares during the period. Pacer Advisors Inc. bought a new position in shares of Natera in the third quarter worth about $106,000. Point72 Hong Kong Ltd bought a new position in shares of Natera in the third quarter worth about $119,000. Finally, Quantbot Technologies LP bought a new position in shares of Natera in the third quarter worth about $135,000. Institutional investors and hedge funds own 89.44% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
Featured Story: Do stock splits help investors?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.